Equities

Portage Biotech Inc

PRTG:NAQ

Portage Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.25
  • Today's Change-0.004 / -1.66%
  • Shares traded94.54k
  • 1 Year change-93.44%
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

  • Revenue in USD (TTM)0.00
  • Net income in USD-144.90m
  • Incorporated--
  • Employees7.00
  • Location
    Portage Biotech IncClarence Thomas Building, Road TownP.O. Box 4649TORTOLA VG1110Virgin Islands (British)VGB
  • Phone+1 4 169291806
  • Fax+1 4 169296612
  • Websitehttps://portagebiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hoth Therapeutics Inc0.00-7.70m4.69m2.00--0.5398-----2.02-2.020.001.780.00----0.00-70.17-157.07-77.15-177.32-----------50.670.00------31.01------
Eiger Biopharmaceuticals Inc15.77m-74.96m4.89m25.00------0.3098-50.80-50.8010.69-9.770.19850.00649.19630,920.00-94.31-60.25-186.10-76.5199.91---475.26-823.590.6809-22.031.54--16.98--22.54--10.51--
Emmaus Life Sciences Inc28.46m-4.74m4.90m55.00------0.1723-0.0931-0.09310.3905-0.67730.63490.81849.36517,454.50-10.58------93.69---16.66--0.12490.1426-----10.77--33.37------
Portage Biotech Inc0.00-144.90m4.95m7.00--0.1545-----7.96-7.960.001.620.00----0.00-111.60-19.70-113.27-26.48------------0.0087-------520.10------
Applied DNA Sciences Inc5.52m-12.50m4.96m53.00------0.8992-17.13-17.137.67-0.05580.389310.384.64104,110.80-87.15-88.57-111.09-121.9133.9844.35-223.89-113.261.54-------26.4327.92-18.73--33.80--
Processa Pharmaceuticals Inc0.00-9.83m5.00m13.00--0.5626-----6.29-6.290.003.110.00----0.00-87.82-84.35-102.32-90.03------------0.0012------59.45---34.05--
MyMD Pharmaceuticals Inc0.00-7.07m5.05m9.00--0.2234-----5.53-5.530.0010.280.00----0.00-25.59-76.20-31.13-84.38--7.64---4,290.96----0.00------49.15------
Halberd Corp281.24k25.34k5.09m3.003.45--200.5118.090.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Galera Therapeutics Inc0.00-45.75m5.11m7.00---------0.9971-0.99710.00-2.480.00----0.00-115.30-83.69-142.79-97.54-----------6.499.23------5.05---29.84--
Pineapple Inc157.59k376.69k5.12m--0.6283--13.4332.470.11140.11140.0028-0.03180.0388------9.28--53.43---412.55--239.03--0.00-----------611.10------
Sonnet Biotherapeutics Holdings Inc92.74k-8.43m5.14m12.00--1.68--55.37-5.28-5.280.03150.98130.0097--0.22487,728.33-87.68---194.11-------9,086.22-----138.210.00---57.76--36.64------
HST Global Inc0.00-141.11k5.14m1.00---------0.0269-0.02690.00-0.11930.00-------29,397.92-5,836.01---------------24.24---------0.7858------
Lipella Pharmaceuticals Inc477.45k-4.74m5.17m5.00--1.87--10.83-0.7633-0.76330.07470.36380.1232--6.2595,490.00-122.37---146.33-------993.39------0.00--144.15---77.81------
Helix BioMedix, Inc.2.07m-2.58m5.23m8.00--3.35--2.53-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Data as of Jun 14 2024. Currency figures normalised to Portage Biotech Inc's reporting currency: US Dollar USD

Institutional shareholders

10.60%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 20241.67m8.42%
Bison Wealth LLCas of 31 Mar 2024213.40k1.08%
Peak6 Capital Management LLCas of 31 Mar 202455.26k0.28%
Millennium Management LLCas of 31 Mar 202432.83k0.17%
Renaissance Technologies LLCas of 31 Mar 202431.66k0.16%
BlackRock Fund Advisorsas of 31 Mar 202428.50k0.14%
Citadel Securities LLCas of 31 Mar 202422.89k0.12%
IEQ Capital LLCas of 31 Mar 202416.65k0.08%
XTX Markets LLCas of 31 Mar 202415.96k0.08%
Brown Brothers Harriman & Co. (Investment Management)as of 31 Mar 202414.00k0.07%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.